J. Verbalis, D. Zeltser, N. Smith
Jul 1, 2008
Citations
3
Influential Citations
67
Citations
Quality indicators
Journal
Clinical Endocrinology
Abstract
Objective and design Most cases of euvolaemic hyponatraemia are associated with elevated plasma levels of AVP. Conivaptan is a high‐affinity, nonpeptide vasopressin V1A/V2‐receptor antagonist. We performed a subgroup analysis of a multicentre, randomized, placebo‐controlled, double‐blind, parallel‐group study to evaluate the efficacy and safety of intravenous (i.v.) conivaptan for the treatment of euvolaemic hyponatraemia.